Alembic Pharmaceuticals is engaged developing formulations and active pharmaceutical ingredients (API).
On a consolidated basis, the pharmaceutical company's net profit rose 37.9% to Rs 234.19 crore on a 18.8% rise in the net sales to Rs 1209.13 crore in Q3 December 2019 over Q3 December 2018.
The scrip was currently down 0.25% at Rs 529.75. It has fallen 19.64% in nine sessions from its recent closing high of Rs 659.25 recorded on 3 March 2020.
